> There's also the fact that study makes it less likely that pre-hospitalization HCQ will have any effect either. We'll see with the U of Minnesota trial, whic

> There's also the fact that study makes it less likely that pre-hospitalization HCQ will have any effect either. We'll see with the U of Minnesota trial, which attempts to use it as post-exposure prophylaxis. Data (hopefully) will tell us. On favipiravir, the data on the Chinese study wasn't exceptional, but wasn't that bad either. Perhaps the Japanese phase 3 study will be more enlightening.